Macrophage recruitment in obese adipose tissue
In the pivotal STEP 1 trial, patients receiving semaglutide 2.4mg weekly achieved average weight loss of 14.9% over 68 weeks
The side effects were similar to the injectable version of Wegovy and were generally mild to moderate in severity, the company said
Medication history: prior GLP-1, GIP, insulin, or sulfonylurea use
It found that patients with diabetes who were prescribed semaglutide, which is marketed as Wegovy and Ozempic, were about four times more likely to be diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that is painless but cannot be treated or cured
Bei verschlsselter Kommunikation knnen Ihre Zahlungsdaten, die Sie an uns bermitteln, nicht von Dritten mitgelesen werden